Company profile
Incendia Therapeutics
Breaking Barriers to Better Cancer Treatment
- Industry
- Biotechnology Research
- Employees
- 24
- Headquarters
- Cambridge, Massachusetts
- LinkedIn followers
- 6,856
- Office locations
- 1
Incendia Therapeutics company summary
Incendia Therapeutics is a company in the Biotechnology Research industry, headquartered in Cambridge, Massachusetts. On LinkedIn the company has around 24 employees and 6,856 followers.
What technology does Incendia Therapeutics use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Incendia Therapeutics
Incendia Therapeutics is a clinical-stage biotechnology company discovering and developing novel monoclonal antibody therapies that disrupt the tumor microenvironment (TME) to improve cancer outcomes. The Company’s science is targeting immune-excluded tumors, an identifiable, prevalent solid tumor phenotype. Incendia’s unique approach breaks down physical and biochemical barriers within the TME to enhance host immune cell infiltration into tumors and enable cancer therapeutics to reach their targets across a broad range of solid cancers. Incendia believes that there are multiple novel opportunities within the TME to target treatment of cancer and improve outcomes. Incendia’s most advanced investigational therapeutic is PRTH-101, a novel therapeutic antibody that binds to and inhibits Discoidin Domain Receptor 1 (DDR1), an element of the TME that is highly expressed by cancer cells in multiple solid tumor types. The Company is currently recruiting patients into a Phase 1c clinical trial with PRTH-101 for the treatment of patients with advanced solid tumors (thymic carcinoma).
Where is Incendia Therapeutics located?
Incendia Therapeutics lists 1 location.
Compare companies similar to Incendia Therapeutics
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Incendia Therapeutics incendiatx.com | Biotechnology Research | 24 | - | Cambridge, Massachusetts |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Incendia Therapeutics
What does Incendia Therapeutics do?
Incendia Therapeutics is a clinical-stage biotechnology company discovering and developing novel monoclonal antibody therapies that disrupt the tumor microenvironment (TME) to improve cancer outcomes. The Company’s science is targeting immune-excluded tumors, an identifiable, prevalent solid tumor phenotype. Incendia’s unique approach breaks down physical and biochemical barriers within the TME to enhance host immune cell infiltration into tumors and enable cancer therapeutics to reach their targets across a broad range of solid cancers. Incendia believes that there are multiple novel opportunities within the TME to target treatment of cancer and improve outcomes. Incendia’s most advanced investigational therapeutic is PRTH-101, a novel therapeutic antibody that binds to and inhibits Discoidin Domain Receptor 1 (DDR1), an element of the TME that is highly expressed by cancer cells in multiple solid tumor types. The Company is currently recruiting patients into a Phase 1c clinical trial with PRTH-101 for the treatment of patients with advanced solid tumors (thymic carcinoma).
How many employees does Incendia Therapeutics have?
Incendia Therapeutics has around 24 employees on LinkedIn.
Where is Incendia Therapeutics headquartered?
Incendia Therapeutics is headquartered in Cambridge, Massachusetts.
Build a lead list from companies like Incendia Therapeutics
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.